Drug Profile
Girentuximab Zr 89 - Heidelberg-Pharma/Telix-Pharmaceuticals
Alternative Names: 177Lu-DOTA-girentuximab; 89Zirconium-labelled Girentuximab; 89Zr-DFO-TFP-girentuximab (GTX); 89Zr-girentuximab; 89Zr-TLX250; 89Zr-DFO-girentuximab; 89Zr-TX250; TLX250 CDx; Zircaix; Zirconium-89 girentuximab; Zr-89-girentuximabLatest Information Update: 06 Feb 2024
Price :
$50
*
At a glance
- Originator WILEX AG
- Developer China Grand Pharmaceutical and Healthcare; Heidelberg Pharma AG; Institut de Cancerologie de l'Ouest; Radbound University Nijmegen; Telix Pharmaceuticals; University of Melbourne
- Class Diagnostic agents; Imaging agents; Monoclonal antibody diagnostics; Radioisotopes; Radiopharmaceutical diagnostics
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Renal cell carcinoma
- Phase II Solid tumours; Triple negative breast cancer
- Phase I Bladder cancer; Urogenital cancer
- Research Colorectal cancer
Most Recent Events
- 31 Jan 2024 Telix Pharmaceuticals completes the phase-II OPALESCENCE trial in Triple-negative-breast cancer (Diagnosis) in France (IV), prior to January 2024 (NCT04758780)
- 19 Dec 2023 Preregistration for Renal cell carcinoma (Diagnosis) in USA (IV)
- 06 Dec 2023 Positive efficacy and adverse events data from a phase II OPALESCENCE trial in Triple negative breast cancer presented at the San Antonio Breast Cancer Symposium® (SABCS-2023)